Abstract
Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. Methods. VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INIresistant virus received DTG 50 mg BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was optimized with ≥1 fully active drug and DTG continued. The primary efficacy endpoints were the mean change from baseline in plasma HIV-1 RNA at day 8 and the proportion of subjects with HIV-1 RNA
| Original language | English |
|---|---|
| Pages (from-to) | 354-362 |
| Number of pages | 9 |
| Journal | Journal of Infectious Diseases |
| Volume | 210 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Aug 1 2014 |
Fingerprint
Keywords
- Dolutegravir
- DTG
- Elvitegravir resistance
- Integrase inhibitor
- Raltegravir resistance
ASJC Scopus subject areas
- Infectious Diseases
- Immunology and Allergy
Cite this
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1 : 24-week results of the phase III VIKING-3 study. / Castagna, Antonella; Maggiolo, Franco; Penco, Giovanni; Wright, David; Mills, Anthony; Grossberg, Robert; Molina, Jean Michel; Chas, Julie; Durant, Jacques; Moreno, Santiago; Doroana, Manuela; Ait-Khaled, Mounir; Huang, Jenny; Min, Sherene; Song, Ivy; Vavro, Cindy; Nichols, Garrett; Yeo, Jane M.
In: Journal of Infectious Diseases, Vol. 210, No. 3, 01.08.2014, p. 354-362.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1
T2 - 24-week results of the phase III VIKING-3 study
AU - Castagna, Antonella
AU - Maggiolo, Franco
AU - Penco, Giovanni
AU - Wright, David
AU - Mills, Anthony
AU - Grossberg, Robert
AU - Molina, Jean Michel
AU - Chas, Julie
AU - Durant, Jacques
AU - Moreno, Santiago
AU - Doroana, Manuela
AU - Ait-Khaled, Mounir
AU - Huang, Jenny
AU - Min, Sherene
AU - Song, Ivy
AU - Vavro, Cindy
AU - Nichols, Garrett
AU - Yeo, Jane M.
PY - 2014/8/1
Y1 - 2014/8/1
N2 - Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. Methods. VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INIresistant virus received DTG 50 mg BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was optimized with ≥1 fully active drug and DTG continued. The primary efficacy endpoints were the mean change from baseline in plasma HIV-1 RNA at day 8 and the proportion of subjects with HIV-1 RNA
AB - Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. Methods. VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INIresistant virus received DTG 50 mg BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was optimized with ≥1 fully active drug and DTG continued. The primary efficacy endpoints were the mean change from baseline in plasma HIV-1 RNA at day 8 and the proportion of subjects with HIV-1 RNA
KW - Dolutegravir
KW - DTG
KW - Elvitegravir resistance
KW - Integrase inhibitor
KW - Raltegravir resistance
UR - http://www.scopus.com/inward/record.url?scp=84898987717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898987717&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiu051
DO - 10.1093/infdis/jiu051
M3 - Article
C2 - 24446523
AN - SCOPUS:84898987717
VL - 210
SP - 354
EP - 362
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 3
ER -